152 related articles for article (PubMed ID: 8981830)
1. [Physicochemical properties of suplatast tosilate racemate and enantiomers].
Ushio T; Endo K; Yamamoto K
Yakugaku Zasshi; 1996 Nov; 116(11):866-75. PubMed ID: 8981830
[TBL] [Abstract][Full Text] [Related]
2. Four new polymorphic forms of suplatast tosilate.
Nagai K; Ushio T; Miura H; Nakamura T; Moribe K; Yamamoto K
Int J Pharm; 2014 Jan; 460(1-2):83-91. PubMed ID: 24211359
[TBL] [Abstract][Full Text] [Related]
3. Formation of solid solutions between racemic and enantiomeric citalopram oxalate.
de Diego HL; Bond AD; Dancer RJ
Chirality; 2011 May; 23(5):408-16. PubMed ID: 21472783
[TBL] [Abstract][Full Text] [Related]
4. Formation of the racemic compound of ephedrine base from a physical mixture of its enantiomers in the solid, liquid, solution, or vapor state.
Duddu SP; Grant DJ
Pharm Res; 1992 Aug; 9(8):1083-91. PubMed ID: 1409382
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of preferential enrichment, an unusual enantiomeric resolution phenomenon caused by polymorphic transition during crystallization of mixed crystals composed of two enantiomers.
Tamura R; Fujimoto D; Lepp Z; Misaki K; Miura H; Takahashi H; Ushio T; Nakai T; Hirotsu K
J Am Chem Soc; 2002 Nov; 124(44):13139-53. PubMed ID: 12405843
[TBL] [Abstract][Full Text] [Related]
6. Racemate and enantiomers of ketoprofen: phase diagram, thermodynamic studies, skin permeability, and use of chiral permeation enhancers.
Kommuru TR; Khan MA; Reddy IK
J Pharm Sci; 1998 Jul; 87(7):833-40. PubMed ID: 9649351
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a solid solution of enantiomers in a racemate-forming system by seeding.
Huang J; Chen S; Guzei IA; Yu L
J Am Chem Soc; 2006 Sep; 128(36):11985-92. PubMed ID: 16953640
[TBL] [Abstract][Full Text] [Related]
8. Suplatast tosilate affects the initial increase in specific IgE and interleukin-4 during immunotherapy for perennial allergic rhinitis.
Washio Y; Ohashi Y; Tanaka A; Kakinoki Y; Sugiura Y; Sakamoto H; Yamada K; Matsuda M; Uekawa M; Okamoto H; Nakai Y
Acta Otolaryngol Suppl; 1998; 538():126-32. PubMed ID: 9879412
[TBL] [Abstract][Full Text] [Related]
9. Relationship among physicochemical properties, skin permeability, and topical activity of the racemic compound and pure enantiomers of a new antifungal.
Wearley L; Antonacci B; Cacciapuoti A; Assenza S; Chaudry I; Eckhart C; Levine N; Loebenberg D; Norris C; Parmegiani R
Pharm Res; 1993 Jan; 10(1):136-40. PubMed ID: 8430050
[TBL] [Abstract][Full Text] [Related]
10. Effects of suplatast tosilate (IPD Capsules) on the production of active oxygen by neutrophils and of IL-8 by mononuclear cells.
Tohda Y; Kubo H; Haraguchi R; Iwanaga T; Fukuoka M
Int Immunopharmacol; 2001 Jun; 1(6):1183-7. PubMed ID: 11407312
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of suplatast tosilate, a Th2 cytokine inhibitor based on the Th1/Th2 ratio for allergic disease in children: a retrospective study.
Yoshihara S; Fukuda H; Arisaka O
Arzneimittelforschung; 2011; 61(7):421-4. PubMed ID: 21899211
[TBL] [Abstract][Full Text] [Related]
12. Suplatast tosilate prevents bleomycin-induced pulmonary fibrosis in mice.
Furonaka M; Hattori N; Tanimoto T; Senoo T; Ishikawa N; Fujitaka K; Haruta Y; Yokoyama A; Kohno N
J Pharmacol Exp Ther; 2009 Jan; 328(1):55-61. PubMed ID: 18832650
[TBL] [Abstract][Full Text] [Related]
13. Preferential enrichment: full crystallographic analysis of the unusual phenomenon in the mixed crystals' version.
Takahashi H; Tamura R; Fujimoto D; Lepp Z; Kobayashi K; Ushio T
Chirality; 2002 Jul; 14(7):541-7. PubMed ID: 12112325
[TBL] [Abstract][Full Text] [Related]
14. [Inhibitory effect of suplatast tosilate on eosinophil migration].
Kobayashi Y; Nagata M; Yamamoto H; Sakamoto Y
Arerugi; 2000 Jul; 49(7):600-3. PubMed ID: 10944827
[TBL] [Abstract][Full Text] [Related]
15. Sobrerol enantiomers and racemates: solid-state spectroscopy, thermal behavior, and phase diagrams.
Bettinetti G; Giordano F; Fronza G; Italia A; Pellegata R; Villa M; Ventura P
J Pharm Sci; 1990 Jun; 79(6):470-5. PubMed ID: 2395091
[TBL] [Abstract][Full Text] [Related]
16. Suplatast tosilate inhibits goblet-cell metaplasia of airway epithelium in sensitized mice.
Shim JJ; Dabbagh K; Takeyama K; Burgel PR; Dao-Pick TP; Ueki IF; Nadel JA
J Allergy Clin Immunol; 2000 Apr; 105(4):739-45. PubMed ID: 10756224
[TBL] [Abstract][Full Text] [Related]
17. Permeability of pure enantiomers of ketorolac through human cadaver skin.
Roy SD; Chatterjee DJ; Manoukian E; Divor A
J Pharm Sci; 1995 Aug; 84(8):987-90. PubMed ID: 7500285
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effects of suplatast tosilate on the differentiation and function of monocyte-derived dendritic cells from patients with asthma.
Tanaka A; Minoguchi K; Samson KT; Oda N; Yokoe T; Tazaki T; Yamamoto Y; Yamamoto M; Ohta S; Adachi M
Clin Exp Allergy; 2007 Jul; 37(7):1083-9. PubMed ID: 17581203
[TBL] [Abstract][Full Text] [Related]
19. Effects of suplatast tosilate on allergic eosinophilic airway inflammation in patients with mild asthma.
Sano Y; Suzuki N; Yamada H; To Y; Ogawa C; Ohta K; Adachi M
J Allergy Clin Immunol; 2003 May; 111(5):958-66. PubMed ID: 12743558
[TBL] [Abstract][Full Text] [Related]
20. [Chronic eosinophilic pneumonia successfully treated with suplatast tosilate].
Hamada H; Sakatani M; Nishioka M; Akira M; Yamamoto S; Ueda E; Okano Y; Nakamura Y; Sone S
Nihon Kyobu Shikkan Gakkai Zasshi; 1997 Jun; 35(6):692-7. PubMed ID: 9294307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
